Source:http://linkedlifedata.com/resource/pubmed/id/21303454
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2011-2-9
|
pubmed:abstractText |
Overexpression of the chemokine monocyte chemotactic protein-1 (MCP-1) has been associated with a poor prognosis in many human cancers. Increased MCP-1 concentrations may promote tumour progression by increasing mobilization of myeloid derived suppressor cells such as immature monocytes and neutrophils. We hypothesized that increased numbers of peripheral neutrophils or monocytes and increased MCP-1 concentrations would predict a worse outcome in dogs with multicentric lymphoma. In this retrospective study involving 26 client-owned dogs diagnosed with lymphoma, we show that peripheral neutrophil and monocyte counts as well as serum MCP-1 concentrations were significantly elevated relative to healthy control animals, and that such increases were associated with a decreased disease-free interval in dogs treated with chemotherapy based on cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP). To our knowledge, this is the first study showing that pretreatment evaluation of monocyte and neutrophil counts can provide important prognostic information in dogs with lymphoma. The mechanisms underlying these observations remain to be determined.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CCL2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1476-5829
|
pubmed:author | |
pubmed:copyrightInfo |
© 2010 Blackwell Publishing Ltd.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
55-64
|
pubmed:meshHeading |
pubmed-meshheading:21303454-Animals,
pubmed-meshheading:21303454-Antineoplastic Agents,
pubmed-meshheading:21303454-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21303454-Chemokine CCL2,
pubmed-meshheading:21303454-Cyclophosphamide,
pubmed-meshheading:21303454-Dog Diseases,
pubmed-meshheading:21303454-Dogs,
pubmed-meshheading:21303454-Doxorubicin,
pubmed-meshheading:21303454-Female,
pubmed-meshheading:21303454-Leukocyte Count,
pubmed-meshheading:21303454-Lymphoma, Non-Hodgkin,
pubmed-meshheading:21303454-Male,
pubmed-meshheading:21303454-Monocytes,
pubmed-meshheading:21303454-Prednisone,
pubmed-meshheading:21303454-Prognosis,
pubmed-meshheading:21303454-Retrospective Studies,
pubmed-meshheading:21303454-Vincristine
|
pubmed:year |
2011
|
pubmed:articleTitle |
Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphoma.
|
pubmed:affiliation |
Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA. sdow@colostate.edu
|
pubmed:publicationType |
Journal Article
|